Merck's Keytruda takes home adjuvant win in melanoma, escalating early-line fight with Bristol Myers
With immune checkpoint inhibitors quickly emerging as standard of care across a broad range of advanced cancers, the biggest drugmakers in the race are making a hard push into earlier lines of therapy to gain an edge. The biggest dog in the fight, Merck, now has data that could spell a quick approval and sales bump.
Keytruda beat out placebo in staving off the recurrence of cancer as an adjuvant therapy in patients with high-risk stage II melanoma after surgery to remove their tumors, according to topline data from the KEYNOTE-716 study released Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.